메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025

SINGAPORE, Dec. 8, 2025 -- BeLive Studios, NewUnivers and ChopChop Systems executed a Memorandum of Understanding (MOU) at the Asia TV Forum and Market (ATF) today. The MOU establishes a strategic framework for collaboration among the three parties in the production, co-production and operational integration of microdrama content. The partnership was initiated through Content IP Xcelerate in Singapore, operated by the Korea Creative Content Agency (KOCCA) Singapore Business Centre, and formally presented during KOCCA's participation at ATF. The signing ceremony was conducted in
- 김장윤(JASON KIM) 기자
- 2025-12-08 11:00
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 8, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product candidate, CT0596, for the treatment of relapsed/refractory multiple myeloma (R/R MM) was presented in a poster at the 67th American Society of Hematology (ASH) Annual Meeting. The poster was titled "A First-in-Human Study of CT0596, an Allogeneic CAR T-Cell Therapy Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma." The publ
- 김갑성 기자
- 2025-12-08 10:08
Traveloka and Singapore Tourism Board launch regional campaign to inspire spontaneous weekend getaways to Singapore

SINGAPORE, Dec. 8, 2025 -- Traveloka, Southeast Asia's leading travel platform, and the Singapore Tourism Board (STB) strengthen their partnership with the launch of a new regional marketing campaign targeting young travellers titled 'A World of Experiences Await'. The initiative aims to position Singapore as a preferred short-haul destination for travellers and repeat visitors seeking spontaneous and convenient getaways from key Southeast Asian markets. When travelling, making the most out of every moment with loved ones is essential. In Singapore, this is made remarka
- 김장윤(JASON KIM) 기자
- 2025-12-08 10:00
Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting

NANJING, China, Dec. 8, 2025 -- From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology ("ASH") was held in Orlando, Florida, USA. Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) delivered an oral presentation on the opening day of the conference featuring the Phase I/II clinical results of LBL-034, a GPRC5D/CD3 bispecific antibody with a unique 2:1 structure and conditional activation, independently developed using the proprietary LeadsBody platform, for the treatment of relapsed/refractor
- 김갑성 기자
- 2025-12-08 10:00
IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH

SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 8, 2025 -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune diseases, announced the oral presentation of updated clinical data for its independently developed, fully human BCMA-targeted CAR-T cell therapy product, Equecabtagene Autoleucel (Eque-cel), for the treatment of transplant-ineligible patients with high-risk newly diagnosed multiple my
- 김갑성 기자
- 2025-12-08 09:57
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3 for the treatment of relapsed or refractory multiple myeloma (R/R MM)
- 김갑성 기자
- 2025-12-08 09:02
Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

SINGAPORE, Dec. 8, 2025 -- The Dulwich College Ranjit Murugason Sustainability Fund is pleased to announce renewed support from LGT Bank Singapore ("LGT"), reinforcing a three-year collaboration that has helped Dulwich College (Singapore) students develop the skills, confidence and guidance needed to deliver meaningful sustainability and community projects across Singapore and the region. The Sustainability Fund sits at the heart of the College's Live Worldwise vision and Guiding Statements, encouraging students to take purposeful action and thoughtfully engage with issues of
- 황정호 기자
- 2025-12-08 09:00
TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

SINGAPORE, Dec. 8, 2025 -- TenPay Global, Tencent's cross-border payment platform, and Mastercard Move, Mastercard's money movement business, have announced a collaboration to facilitate fast, secure and transparent digital remittances directly to Weixin Pay, a leading mobile payment service within the Weixin ecosystem in China. Through Mastercard Move, Mastercard's portfolio of money movement capabilities, eligible senders around the world will be able to send salaries and family support directly to Weixin Pay Wallet Balance or linked bank cards in Weixin Pay. According to the
- 황정호 기자
- 2025-12-08 09:00
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall survival not yet reached and is projected to exceed four years, which would surpass osimertinib monotherapy by more than one year. -- Johnson & Johnson today announced final overall survival (OS) results from the Asia patients of the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib monotherapy showed amivantamab plus lazertinib led to a clinically meanin
- 김갑성 기자
- 2025-12-08 09:00
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

TOKYO, Dec. 8, 2025 -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 70 million (USD 460,0001) for the development of a prototype detection test for mpox (formerly known as monkeypox2). Mpox is a viral infectious disease that has been spreading in the Democratic Republic of the Congo (DRC) and across sub-Saharan Africa. According to a situation report by the World Health Organization (WHO), more than 170,000 cases of mpox were confirmed in 141 countries between January 2022 and October 20253. WHO also reported that surveillance d
- 김갑성 기자
- 2025-12-08 09:00

이전

91 92 93 94 95 96 97 98 99 100

많이 본 기사

최근기사

2026-01-12_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 12일 15시 00분